- Home
- CODX vs BIAF Comparison
CODX vs BIAF Comparison
Compare CODX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- BIAF
- Stock Information
- Founded
- CODX 2013
- BIAF 2014
- Country
- CODX United States
- BIAF United States
- Employees
- CODX N/A
- BIAF N/A
- Industry
- CODX Medical/Dental Instruments
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CODX Health Care
- BIAF Health Care
- Exchange
- CODX Nasdaq
- BIAF Nasdaq
- Market Cap
- CODX 11.9M
- BIAF 12.2M
- IPO Year
- CODX 2017
- BIAF 2022
- Fundamental
- Price
- CODX $0.26
- BIAF $0.26
- Analyst Decision
- CODX Buy
- BIAF Hold
- Analyst Count
- CODX 2
- BIAF 1
- Target Price
- CODX $5.50
- BIAF N/A
- AVG Volume (30 Days)
- CODX 606.2K
- BIAF 9.4M
- Earning Date
- CODX 05-08-2025
- BIAF 05-15-2025
- Dividend Yield
- CODX N/A
- BIAF N/A
- EPS Growth
- CODX N/A
- BIAF N/A
- EPS
- CODX N/A
- BIAF N/A
- Revenue
- CODX $3,497,583.00
- BIAF $8,809,228.00
- Revenue This Year
- CODX N/A
- BIAF N/A
- Revenue Next Year
- CODX $42.11
- BIAF $19.99
- P/E Ratio
- CODX N/A
- BIAF N/A
- Revenue Growth
- CODX N/A
- BIAF 78.40
- 52 Week Low
- CODX $0.23
- BIAF $0.16
- 52 Week High
- CODX $2.23
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- CODX 38.53
- BIAF 43.83
- Support Level
- CODX $0.23
- BIAF $0.24
- Resistance Level
- CODX $0.34
- BIAF $0.50
- Average True Range (ATR)
- CODX 0.06
- BIAF 0.07
- MACD
- CODX -0.00
- BIAF 0.01
- Stochastic Oscillator
- CODX 12.21
- BIAF 24.67
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.